Literature DB >> 12782801

Adenocarcinoma ex-pleomorphic adenoma of the lacrimal sac and nasolacrimal duct: a case report.

Soly Baredes1, Danielle B Ludwin, Yolanda L Troublefield, Paul D Langer, Neena Mirani.   

Abstract

OBJECTIVES: To present the clinical presentation, workup, surgical approach, and pathological findings of the first case report of a patient with adenocarcinoma ex-pleomorphic adenoma of the lacrimal sac and nasolacrimal duct. STUDY
DESIGN: Retrospective review of the records of a case of adenocarcinoma ex-pleomorphic adenoma of the lacrimal sac and nasolacrimal duct.
METHODS: The clinical presentation, workup, surgical approach, and pathological findings were reviewed.
RESULTS: A 51-year-old man presented with a 10-year history of recurrent epiphora of the right eye. At dacryocystorhinostomy a small lesion was visualized within the lumen of the lacrimal sac. A biopsy specimen was consistent with adenocarcinoma. En bloc resection was accomplished using a lateral rhinotomy and medial maxillectomy. The final specimen showed adenocarcinoma ex-pleomorphic adenoma. The patient was given postoperative radiation therapy. He was free of disease 16 months after treatment.
CONCLUSIONS: Lacrimal sac tumors should be considered in the differential diagnosis of chronic epiphora. Management of nasolacrimal adenocarcinoma requires complete surgical resection. Radiation treatment in and of itself is not curative but may be useful as adjuvant therapy. Carcinoma ex-pleomorphic adenoma can develop in the lacrimal sac and nasolacrimal duct.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12782801     DOI: 10.1097/00005537-200306000-00005

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  12 in total

1.  Primary nasolacrimal duct malignant mucosal melanoma.

Authors:  A M Lewis; P M Clarke; J M Olver
Journal:  Br J Ophthalmol       Date:  2006-01       Impact factor: 4.638

Review 2.  Carcinoma ex pleomorphic adenoma: a comprehensive review of clinical, pathological and molecular data.

Authors:  Joyce Antony; Vinod Gopalan; Robert A Smith; Alfred K Y Lam
Journal:  Head Neck Pathol       Date:  2011-07-09

Review 3.  Primary ductal adenocarcinoma of the lacrimal sac: the first reported case.

Authors:  Mitsuaki Ishida; Muneo Iwai; Keiko Yoshida; Akiko Kagotani; Hideaki Kohzaki; Masahiko Arikata; Takeshi Shimizu; Hidetoshi Okabe
Journal:  Int J Clin Exp Pathol       Date:  2013-08-15

4.  Rare Carcinoma Ex-pleomorphic Adenoma of Buccal Mucosa: Case Report and Review of Literature.

Authors:  Prashant Goyal; Shelly Sehgal; Soumyesh Ghosh; Dipti Agrawal; Sompal Singh
Journal:  Rare Tumors       Date:  2016-03-21

5.  Squamous cell carcinoma of the nasolacrimal duct.

Authors:  Hiroshi Sakaida; Masayoshi Kobayashi; Atsushi Yuta; Yoshinori Imanishi; Yuichi Majima
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-05-17       Impact factor: 2.503

6.  Carcinoma ex pleomorphic adenoma originating from ectopic salivary gland in the neck region: case report.

Authors:  Onur Ismı; Yusuf Vayısoğlu; Rabia Bozdogan Arpaci; Can Eti; Tuğçe Pütürgeli; Kemal Gorur; Cengiz Ozcan
Journal:  Gland Surg       Date:  2015-12

7.  [Adenocarcinoma in the tear sack after endonasal dacryocystorhinostomy].

Authors:  C S Betz; A Leunig; P Janda; R Jund
Journal:  HNO       Date:  2005-03       Impact factor: 1.284

8.  Pedunculated carcinoma ex pleomorphic adenoma of the nasal cavity: A unique case report.

Authors:  Po-Wu Liao; Yen-Lin Chen; Jeng-Wen Chen
Journal:  Medicine (Baltimore)       Date:  2016-09       Impact factor: 1.889

Review 9.  Pleomorphic adenoma of the lacrimal gland: A review with updates on malignant transformation and molecular genetics.

Authors:  William Harrison; Patricia Pittman; Thomas Cummings
Journal:  Saudi J Ophthalmol       Date:  2018-03-02

10.  Lacrimal sac adenocarcinoma managed with androgen deprivation.

Authors:  David H Abramson; Julia Fallon; Noa Biran; Jasmine H Francis; Korey Jaben; William K Oh
Journal:  Am J Ophthalmol Case Rep       Date:  2020-07-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.